Washington, D.C. –Today the Food and Drug Administration (FDA) announced the agency’s decision to revoke Avastin’s approval as a metastatic breast cancer treatment drug. 

“I am deeply disappointed in the FDA decision to remove the metastatic breast cancer indication from the Avastin label,” said Granger.  “I have spoken to oncologists in my district who value Avastin as an effective tool in fighting this horrible disease.  I encourage Medicare to continue to cover Avastin for breast cancer.  For some women in my district, this therapy is their only hope.”